Mostly Markets
Subscribe
Stocks/Health Care/Health Care Services

LabcorpLH

Health Care Services · Burlington, North Carolina · In the S&P 500
$361.39−1.84%After hours: $361.39 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 45.6% over 1 year
Labcorp over 1 yearDaily close, $, to 30 Oct 2026
$250$300$350Nov2026MarMayJulSep$361.39$250$300$350NovMarJul$361.39
Source: Nasdaq daily closes
Market value$29.34B
Price to earnings29.6x
Forward P/E19.1x
Dividend yield0.80%
Year to date+44.0%
One year+45.6%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$246.64$368.16

Quality and valuation

How Labcorp compares with other health care stocks. A description, not a recommendation.

Labcorp and 5 health care services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: weaker than mostValuation: in line with its sector

A weaker business than most health care companies, priced about in line with them.

Labcorp trades at 19.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +6.0% vs +7.8%
  • Keeps less of each sale (gross margin): 29.0% vs 65.3%
  • Less profitable (operating margin): 10.3% vs 13.3%
  • Turns less of its sales into cash: 8.8% vs 15.9%
LH trades at 19.1x forward earnings, above the sector medianForward p/e, Health Care Services peers
CI9.4xCVS11.1xDVA11.9xLH19.1xDGX22.2xHIMS73.4xSector median 19.1xCI9.4xCVS11.1xDVA11.9xLH19.1xDGX22.2xHIMS73.4xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 29.6x earnings, LH is pricier than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
40xAverage 29.5x2025202629.6x40xAverage 29.5x2025202629.6x
Source: Nasdaq prices; SEC filings

Financials

From Labcorp's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 6.9% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$1bn$2bn$3bnQ4 ’24Q2 ’25Q4 ’25$3.8bnQ3 ’26$0bn$2bnQ4 ’24Q2 ’25Q4 ’25$3.8bnQ3 ’26
Source: SEC filings
Growth sped up to +6.9% last quarterRevenue growth, year on year, %
0%2%5%8%Q4 ’24Q2 ’25Q4 ’256.9%Q3 ’260%5%Q4 ’24Q2 ’25Q4 ’256.9%Q3 ’26
Source: SEC filings
Operating margin was 10.6% last quarterOperating income as a share of revenue, %
0%5%10%Q4 ’24Q2 ’25Q4 ’2510.6%Q3 ’260%5%10%Q4 ’24Q2 ’25Q4 ’2510.6%Q3 ’26
Source: SEC filings
Free cash flow was $1.3 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400m$600mQ4 ’24Q2 ’25Q4 ’25$412mQ3 ’26$0m$500mQ4 ’24Q2 ’25Q4 ’25$412mQ3 ’26
Source: SEC filings
Last 12 monthsLHSector median
Revenue growth+6.0%+7.8%
Gross margin29.0%65.3%
Operating margin10.3%13.3%
Free cash flow margin8.8%15.9%
Price to earnings29.6x30.2x

Stories on Labcorp

We haven't written about Labcorp yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Services, by market value.

CompanyPriceTodayYTDValue
CVSCVS Health$90.25−0.09%+13.7%$115B
CICigna$298.23−0.06%+8.4%$78.80B
DGXQuest Diagnostics$251.82−0.43%+45.1%$27.70B
DVADaVita$187.50−3.01%+65.0%$11.96B
HIMSHims & Hers Health$27.68−6.71%−14.8%$6.46B